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Abstract A missense mutation of Smad2 identified in cancer
cells was reconstructed on the corresponding residue of Smad3.
This mutant, Smad3D407E, was not phosphorylated by the
constitutively active form of type I receptor for transforming
growth factor-L (TGF-L), and inhibited the phosphorylation of
co-expressed wild-type Smad2 and Smad3. This mutant also had
a dominant negative effect on the growth inhibition of HaCaT
cells and on the expression of p3TP-lux reporter gene induced by
TGF-L. However, it did not alter the phosphorylation of Smad1
induced by the constitutively active form of the bone morphoge-
netic protein type IA receptor. These findings showed that a
single missense mutation in Smad3 could specifically block TGF-
L signals by preventing activation of both Smad2 and Smad3.
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1. Introduction
Transforming growth factor-L (TGF-L) is a multifunctional
peptide factor which regulates cell proliferation, di¡erentia-
tion, adhesion, apoptosis, and extracellular matrix accumula-
tion [1]. TGF-L binds to type II and type I serine/threonine
kinase receptors, and transduces intracellular signals through
Smad proteins [2,3]. Of eight reported mammalian Smad pro-
teins, Smad2 and Smad3 have been shown to be directly phos-
phorylated by TGF-L type I receptor (TLR-I) on the C-ter-
minal SSXS motif, form hetero-oligomers with Smad4,
translocate into nuclei, and serve as components of transcrip-
tion factors upon TGF-L stimulation [4^13]. Overexpression
of Smad2 and/or Smad3 together with Smad4 stimulates
TGF-L-responsive gene expression, and C-terminally mutated
Smads have dominant negative e¡ects on TGF-L signals
[5,6,14].
Many cancer cells exhibit de¢cient growth inhibitory re-
sponses to TGF-L [1,15]. Mutations of the TGF-L type II
receptor (TLR-II) are a frequent known cause of this de¢-
ciency. More than 90% of cases of hereditary non-polypotic
colon cancer had inactivating mutations in the TLR-II gene
[16], and the loss of functional TLR-II was responsible for the
loss of TGF-L responsiveness [17]. Mutations in the Smad
genes have also been found in various cancers. The DPC4/
Smad4 gene was originally identi¢ed as a candidate tumor
suppressor gene at 18q21.1 [18]. Homozygous deletions at
18q21 were found in about 30% of human pancreatic cancers,
and potentially inactivating mutations in the DPC4/Smad4
gene were identi¢ed in about 20% of pancreatic cancers.
DPC4/Smad4 has been shown to act as a common mediator
in the signaling pathways for the members in the TGF-L
superfamily [7,19]. Mutations in the DPC4/Smad4 gene have
also been identi¢ed less frequently in colorectal cancers, lung
cancers, breast cancers, ovarian cancers, and head and neck
cancers [20^24], and the loss of DPC4/Smad4 has been shown
to be responsible for the loss of TGF-L responsiveness in
some cases [25,26]. Similar mutations were also detected in
the Smad2 gene in colorectal cancers and lung cancers [4,27].
Smad3 is also thought to play a role in the TGF-L-induced
growth inhibitory signaling pathway [6,14]. However, the
Smad3 mutation has not yet been identi¢ed in cancer cells
[28,29]. It is unclear if Smad3 could also perturb TGF-L sig-
naling by oncogenic mutations identi¢ed in Smad2 or Smad4.
A missense mutation of Asp-450 to Glu in Smad2 was orig-
inally reported in a case of colorectal cancer [4]. This mutant
was defective in TGF-L receptor-dependent phosphorylation.
Another mutation was found on the same residue of Smad2 in
a case of lung cancer [27]. The corresponding aspartic acid
residue (Asp-537) was located at the trimer interface in the
crystal structure of Smad4, and a Smad4D537E mutant was
defective in oligomer formation [30]. In the present study, we
introduced this mostly characterized oncogenic mutation of
Smad2 into the corresponding residue of Smad3, and exam-
ined the role of a Smad3D407E mutant in the TGF-L signal-
ing pathway.
2. Materials and methods
2.1. Constructs and reagents
Smad3 cDNA and Smad4 cDNA were provided by R. Derynck
(University of California, San Francisco, CA) and M. Schutte (Johns
Hopkins University, Baltimore, MD), respectively. Expression con-
structs for various Smad proteins and constitutively active forms of
TGF-L type I receptor (TLR-I(TD)/HA) and BMP type IA receptor
(BMPR-IA(QD)/HA) were previously described [9]. Mutations and
sequences of the exchanged restriction fragments in Smad3 were con-
¢rmed by DNA sequencing. Recombinant human TGF-L3 was pro-
vided by A. Suter (Ciba-Geigy, Basel, Switzerland). Anti-Flag anti-
bodies (M2), anti-Myc antibodies (9E10), anti-HA antibodies
(12CA5), and anti-phosphoserine antibodies were purchased from
Eastman Kodak (New Haven, CT), Santa Cruz Biotechnology (Santa
Cruz, CA), Boehringer Mannheim (Indianapolis, IN), and Zymed
Laboratories (South San Francisco, CA), respectively.
2.2. Cell culture and transfections
COS7 cells were obtained from American Type Culture Collection
(Bethesda, MD) and R mutant cells of Mv1Lu (clone 4-2) were pro-
vided by J. MassagueŁ (Memorial Sloan Kettering Cancer Center,
NY). These cells were cultured in Dulbecco’s modi¢ed Eagle’s me-
dium (DMEM) with 10% fetal bovine serum (FBS) and 10 Wg/ml
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gentamicin. HaCaT cells were provided by Norbert E. Fusenig
(DKFZ, Heidelberg, Germany), and maintained in MCDB 153 me-
dium (Sigma, St. Louis, MO) supplemented with 10% dialyzed FBS,
epidermal growth factor (10 ng/ml) and gentamicin (10 Wg/ml) [31].
For transient transfection, 60^80% con£uent cells in 6-well plates were
transfected using DMRIE-C (Life Technologies, Gaithersburg, MD)
or FuGENE 6 (Boehringer Mannheim) transfection reagents follow-
ing the manufacturer’s recommendations. To establish stable trans-
fectants from HaCaT cells, 300 Wg/ml of G418 (Life Technologies)
was used for selection.
2.3. Immunoprecipitation and immunoblotting
For determination of levels of phosphorylation of Smad proteins,
cell lysates were subjected to immunoprecipitation with the anti-Flag
antibody followed by adsorption to protein G Sepharose (Pharmacia
Biotech, Uppsala, Sweden). Precipitates were separated by SDS-poly-
acrylamide gel electrophoresis (SDS-PAGE) and transferred to Pro-
Blott membranes (Applied Biosystems, Foster City, CA). After im-
munoblotting with anti-phosphoserine antibodies, the membranes
were subjected to re-blotting with the anti-Flag antibody to con¢rm
levels of expression of Flag-tagged Smad proteins. To determine levels
of expression of the receptors and Smad3D407E, aliquots of cell ly-
sates were subjected to SDS-PAGE and immunoblotting with anti-
HA, anti-Myc or anti-Flag antibodies, as indicated.
2.4. Luciferase assay
R mutant Mv1Lu cells were transiently transfected with p3TP-lux
in the presence of various combinations of Smad and the receptor
constructs. After transfection, cells were incubated for 24 h, and lu-
ciferase activities in the cell lysates were measured with a dual lucifer-
ase reporter assay system (Promega Biotech, Madison, WI) according
to the manufacturer’s recommendations, using a luminometer (Lumat
LB 9501, EGpG Berthold, Bad Wildbad, Germany).
2.5. Growth inhibition assay
HaCaT cells and the stable transfectants were seeded in 24-well
plates at a density of 5U104 cells per well, and [3H]thymidine incor-
poration was assayed as previously described [31].
3. Results
Asp-407 in Smad3 is conserved in all known Smad proteins
(Fig. 1A). This aspartic acid, which is located at the possible
homo-oligomerization interface in Smad4, was replaced by
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Fig. 1. A single missense mutant of Smad3 was defective in phos-
phorylation induced by TGF-L signaling. A: A schematic represen-
tation of Smad proteins and alignments of highly conserved C-ter-
minal amino acid sequences of Smad1, Smad2, Smad3 and Smad4.
Conserved amino acids are boxed. The location of the induced mis-
sense mutation in Smad3 and corresponding aspartic acid residues
in other Smads is shaded. B: COS7 cells were transfected with wild-
type (wt) or D407E mutant (DE) of Flag-tagged Smad3 in the pres-
ence or absence of a constitutively active form of TGF-L type I re-
ceptor (TLR-I(TD)/HA). Cell lysates were subjected to immunopre-
cipitation using the anti-Flag antibody, and precipitates were
analyzed by SDS-PAGE followed by immunoblotting with anti-
phosphoserine antibodies (anti-P-Ser). The membrane was re-blotted
with the anti-Flag antibody to demonstrate equal levels of expres-
sion of Smad3 and Smad3D407E. Aliquots of cell lysates were also
subjected to immunoblotting with anti-HA antibodies to detect ex-
pression of TLR-I(TD).
Fig. 2. Smad3D407E mutant dominantly blocked the phosphoryla-
tion of co-expressed wild-type Smads in a pathway-speci¢c manner.
A: COS7 cells were transfected with Flag-Smad2 (wt; 2) or Flag-
Smad3 (wt; 3) in the presence or absence of Myc-Smad3D407E and
TLR-I(TD)/HA, as indicated. B: COS7 cells were transfected with
Flag-Smad1 in the presence or absence of Myc-Smad3D407E (DE-
Smad3) and BMPR-IA(QD)/HA, as indicated. Cell lysates were sub-
jected to immunoprecipitation using the anti-Flag antibody, and
precipitates were analyzed by SDS-PAGE followed by immunoblot-
ting with anti-phosphoserine antibodies (anti-P-Ser). The membrane
was re-blotted with the anti-Flag antibody to demonstrate compara-
ble levels of expression of wild-type Smad2, Smad3 (A) and Smad1
(B). Aliquots of cell lysates were also subjected to immunoblotting
with anti-HA antibodies to detect similar levels of expression of
TLR-I(TD)/HA (A) or BMPR-IA(QD)/HA (B). Smad3D407E was
detected by anti-Myc antibodies.
D. Goto et al./FEBS Letters 430 (1998) 201^204202
glutamic acid to construct a Smad3D407E mutant. COS7 cells
were transfected with the Smad3 or Smad3D407E expression
constructs together in presence or absence of the constitutively
active form of TLR-I, TLR-I(TD). Wild-type Smad3 and
Smad3D407E had similar protein expression levels, and phos-
phorylation of the wild-type Smad3 was detected by immuno-
blotting using the antibodies to phosphorylated serine resi-
dues. However, Smad3D407E was defective in TGF-L-
induced phosphorylation (Fig. 1B), as previously reported
for the corresponding mutant of Smad2, Smad2D450E [4].
Smad3D407E also blocked the phosphorylation of co-ex-
pressed wild-type Smad2 and Smad3 (Fig. 2A). Phosphoryla-
tion of Smad1 by the constitutively active form of bone mor-
phogenetic protein (BMP) type IA receptor was not a¡ected
by the mutant, suggesting that the inhibition was pathway-
speci¢c (Fig. 2B).
To determine the functional signi¢cance of Smad3D407E,
we next assayed the e¡ects of this mutant on TGF-L-induced
transcriptional activation using the p3TP-lux promoter re-
porter construct. Luciferase activities were induced by TLR-
I(TD), and were further enhanced by co-transfection of
Smad3 or of Smad2 and Smad4. Expression of Smad3D407E
reduced the luciferase activities induced by Smad3 or by
Smad2 and Smad4 in a dose-dependent manner (Fig. 3).
We have also established HaCaT cells stably expressing
Flag-tagged Smad3D407E. Expression levels of the mutant
Smad3 in the stable transfectants were determined by immu-
noblotting using the anti-Flag antibody (Fig. 4A), and growth
inhibition was measured by [3H]thymidine incorporation as-
say. Expression of Smad3D407E clearly reduced the TGF-L-
induced growth inhibitory response, and the degree of reduc-
tion of inhibition correlated with the levels of expression of
the mutant protein (Fig. 4B). These ¢ndings again suggested
the dominant negative function of Smad3D407E in the TGF-
L signaling pathway.
4. Discussion
Among three Smad proteins involved in TGF-L signaling,
mutations in the Smad4 gene and Smad2 gene have been
identi¢ed in pancreatic cancers, colorectal cancers, lung can-
cers, breast cancers, ovarian cancers, and head and neck can-
cers [4,20^24,27]. Mutations in the Smad3 gene have not yet
been identi¢ed in any cancer [28,29]. However, the present
¢ndings showed that Smad3 could also perturb TGF-L signal-
ing by a mutation identi¢ed in Smad2 in a case of colorectal
cancer.
Smad3 is implicated in the TGF-L-induced growth inhibi-
tory signaling pathway because mutant Smad3 proteins abro-
gate the growth inhibition [6,14]. The present study showed
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Fig. 3. Smad3D407E blocked TGF-L-induced gene expression. R
mutant cells of Mv1Lu (clone 4-2) were transiently transfected with
p3TP-Lux together with various combinations of TLR-I(TD)/HA,
Smad2, Smad3, Smad4 and Smad3D407E, as indicated. The content
of DNA was adjusted to 2 Wg/well by pcDNA3 (Invitrogen). Luci-
ferase activities were normalized to pRL-TK activities to control for
transfection e⁄ciencies. Duplicate experiments were repeated three
times with similar results.
Fig. 4. Smad3D407E generates resistance to TGF-L-induced growth
inhibition. A: HaCaT cells were stably transfected with the Flag-
Smad3D407E expression construct, and the levels of expression in
clones 3, 4, and 9 were assayed by immunoblotting using the anti-
Flag antibody. A mock-transfected cell line (M) was used as a nega-
tive control. B: HaCaT cells (a), mock transfectant (E), and clone
3 (O), clone 4 (F) and clone 9 (b) of Smad3D407E transfectants es-
tablished from HaCaT cells were subjected to [3H]thymidine incor-
poration assay in the presence of various concentrations of TGF-L.
Duplicate experiments were repeated three times with similar results.
Error bars represent S.E.M. Inhibition of thymidine incorporation
at 100 pM of TGF-L was signi¢cantly reduced in clone 4 and clone
9 compared to that in HaCaT and mock transfectant cells
(*P6 0.001, **P6 0.01, Student’s t-test).
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that a single missense mutation in the Smad3 gene could also
result in perturbation of TGF-L signaling. However, this does
not prove a non-redundant role for Smad3 in TGF-L signal-
ing, since the Smad3D407E mutant inhibited the phosphoryl-
ation of both Smad2 and Smad3. Recently, the L3 loop of
Smad proteins was found to determine the speci¢city of inter-
action between Smad proteins and receptors. Smad2 and
Smad3 have identical amino acid sequences in the L3 loop,
suggesting that they share the same binding site to the recep-
tor. Smad1 and Smad5, which mediates BMP signals, also
share identical sequences in the L3 loop, and their sequence
di¡ers at two positions from the Smad2/3 sequences. Swap-
ping these two amino acids in Smad1 and Smad2 caused a
switch in phosphorylation of Smad1 and Smad2 by the BMP
and TGF-L receptors, suggesting that the L3 loops determine
speci¢cities of binding to the receptors [32].
Phosphorylation of Smad proteins has been suspected to
reduce the a⁄nity of Smads to the receptors, and stable bind-
ing of Smads to the receptors was obtained using kinase-de-
fective type I receptors [5]. Similar stable binding was ob-
served with phosphorylation site mutants of Smad2 as well
as the inhibitory Smads, i.e. Smad6 and Smad7 [5,10,11,33^
35]. In all these cases, Smad proteins bound to the receptors
but were not phosphorylated. Smad3D407E also stably bound
to the TGF-L type I receptor (data not shown), and as a result
probably eliminated access of the wild-type Smads to the
binding site. Since the D407E mutation in Smad3 does not
a¡ect the L3 loop, the speci¢city of binding to the receptor
may not be modi¢ed, and thus the mutant may act in a lin-
eage-speci¢c manner.
Smad3D407E had dominant negative e¡ects on growth in-
hibition of HaCaT cells and p3TP-lux gene expression by
TGF-L. However, our ¢ndings do not show that either
Smad2 or Smad3, or both Smad2 and Smad3 are required
for growth inhibitory signaling by TGF-L. Further studies
will be required to elucidate the di¡erent roles of Smad2
and Smad3 in the TGF-L signaling pathway.
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